The recent ECTRIMS/ACTRIMS joint congress in Amsterdam reported results from several pivotal phase III studies. The encouraging results of phase III studies of several new agents and their potential regulatory approval within the next few years promises to add many more therapeutic options and much greater complexity to the multiple sclerosis treatment landscape.
Patients with clinically isolated syndrome, early, or mild disease will likely still begin with one of the first-generation...